In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Immunovant (IMVT – Research Report), with a price target of $47.00. The company’s shares closed yesterday at $36.18.
Thompson CFA covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Argenx Se, and MoonLake Immunotherapeutics. According to TipRanks, Thompson CFA has an average return of 8.9% and a 58.97% success rate on recommended stocks.
Currently, the analyst consensus on Immunovant is a Strong Buy with an average price target of $49.36, implying a 36.43% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $57.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $44.70 and a one-year low of $14.05. Currently, Immunovant has an average volume of 2.43M.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IMVT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immunovant (IMVT) Company Description:
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
Read More on IMVT:
- Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
- Immunovant initiated with bullish view at Deutsche Bank, here’s why
- TD Cowen starts ‘only pure-play TL1A company’ Spyre Therapeutics at Outperform
- Roivant notes Immunovant data from Phase 1 IMVT-1402 trial
- Immunovant announces results from 600 mg MAD cohort of Phase 1 IMVT-1402 trial
